Azithromycin for primary ciliary dyskinesia: a milestone
- 1 May 2020
- journal article
- editorial
- Published by Elsevier
- Vol. 8 (5) , 429-430
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Non-cystic fibrosis bronchiectasis in children and adolescents: Neglected and emerging issuesPediatrics & Neonatology, 2020
- Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trialThe Lancet Respiratory Medicine, 2020
- Primary ciliary dyskinesia in the genomics ageThe Lancet Respiratory Medicine, 2020
- Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic FibrosisAnnals of the American Thoracic Society, 2020
- ERS and ATS diagnostic guidelines for primary ciliary dyskinesia: similarities and differences in approach to diagnosisEuropean Respiratory Journal, 2019
- Classification, Ontology, and Precision MedicineNew England Journal of Medicine, 2018
- Primary Ciliary Dyskinesia: An Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment StrategiesFrontiers in Pediatrics, 2017
- Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference NetworksEuropean Respiratory Journal, 2017
- Proceedings of the COST action BM1407 inaugural conference BEAT-PCD: translational research in primary ciliary dyskinesia - bench, bedside, and population perspectivesBMC Proceedings, 2016
- Improvement of Survival in Patients with Diffuse Panbronchiolitis Treated with Low-dose ErythromycinAmerican Journal of Respiratory and Critical Care Medicine, 1998